Key terms

About ACRS

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through the Therapeutics and Contract Research segments. The Therapeutics segment focuses on identifying, developing, and commercializing different therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Wayne, PA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest ACRS news

Mar 19 4:43pm ET Board Changes Ahead of Aclaris Therapeutics Annual Meeting by TipRanks Mar 01 1:08am ET Aclaris Therapeutics: Hold Rating Amidst Strategic Review and Clinical Setbacks by TipRanks Feb 27 7:07am ET Aclaris Therapeutics reports Q4 EPS (2c), consensus (34c) by TipRanks Feb 06 4:53am ET Aclaris Therapeutics Executive Team Undergoes Major Changes by TipRanks Jan 22 6:07am ET Aclaris Therapeutics downgraded to Neutral from Buy at H.C. Wainwright by TipRanks Jan 20 3:04am ET Aclaris Therapeutics Announces Executive Leadership Changes by TipRanks Jan 16 5:25am ET Aclaris Therapeutics (ACRS) was downgraded to a Hold Rating at BTIG by TipRanks Jan 15 12:20am ET Analysts Offer Insights on Healthcare Companies: Xeris Pharmaceuticals (XERS), Aclaris Therapeutics (ACRS) and Quanterix (QTRX) by TipRanks Jan 11 6:17am ET Aclaris Therapeutics downgraded to Neutral from Buy at BTIG by TipRanks Jan 10 11:26am ET Aclaris downgraded to Hold at Jefferies after ATI-1777 data reported by TipRanks Jan 10 11:21am ET Aclaris Therapeutics downgraded to Hold from Buy at Jefferies by TipRanks Jan 10 7:07am ET Aclaris announces Phase 2b study of ATI-1777 met primary efficacy endpoint by TipRanks Jan 02 7:02am ET Analysts Offer Insights on Healthcare Companies: GoodRx Holdings (GDRX), Aclaris Therapeutics (ACRS) and Ocular Therapeutix (OCUL) by TipRanks Dec 31 5:07am ET BTIG Sticks to Its Buy Rating for Aclaris Therapeutics (ACRS) by TipRanks Dec 29 8:45am ET Buy Rating Justified by Aclaris Therapeutics’ Strategic Focus and Robust Financial Management by TipRanks Dec 21 1:29am ET Aclaris Therapeutics: Strategic Shift and Hold Rating Amidst Clinical Setbacks and Reorganization by TipRanks Dec 20 9:05pm ET Stifel Nicolaus Keeps Their Hold Rating on Aclaris Therapeutics (ACRS) by TipRanks

No recent press releases are available for ACRS

ACRS Financials

1-year income & revenue

Key terms

ACRS Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

ACRS Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

NEW YORK, NEW YORK - FEBRUARY 08: A New York Community Bank stands in Brooklyn on February 08, 2024 in New York City. New York Community Bancorp, a regional lender, shed about 60% of its value over the past eight days and its credit rating has been downgraded to Junk by Moody's. (Photo by Spencer Platt/Getty Images)
Spencer Platt/Getty Images
US regional banks are still under pressure. That’s likely to continue
Trump Media, which runs the social media platform Truth Social, took the place of Digital World's place on the Nasdaq stock exchange in March.
Frank Franklin II/AP
Trump Media stock ends session 15% higher after two very bad days
Students at Highlands High School, work on a practice test at the ACT Boot Camp in Newport, Ky.
Patrick Reddy/The Enquirer/AP/File
Private equity finds its next bet: college admissions
In this photo illustration, Republican presidential candidate former President Donald Trump's social media platform Truth Social is shown on a cell phone on March 25, 2024 in Chicago, Illinois.
Scott Olson/Getty Images
Trump’s stock tumbles again after Truth Social announces it’s getting into streaming